Literature DB >> 21272684

Thyroid stunning: fact or fiction?

I Ross McDougall1, Andrei Iagaru.   

Abstract

Stunning of thyroid tissue by diagnostic activities of (131)I has been described by some investigators and refuted by others. The support both for and against stunning has at times been enthusiastic and vigorous. We present the data from both sides of the debate in an attempt to highlight the strengths and deficiencies in the investigations cited. Clinical, animal, and in vitro studies are included. There are considerable differences in clinical practice, such as the administered activity for diagnostic whole-body scan, delay between diagnostic scan and treatment, time between treatment and posttherapy scanning, and timing of follow-up studies, that have to be analyzed with care. Other factors that often cannot be judged, such as levels of thyroid-stimulating hormone and serum iodine at time of diagnostic testing versus treatment could have an influence on stunning. Larger diagnostic doses and longer delays to therapy appear to increase the likelihood of stunning. The stunning effect of early-absorbed radiation from the therapy should also be considered.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272684     DOI: 10.1053/j.semnuclmed.2010.10.004

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  14 in total

1.  Comparing pre-therapeutic 124I and 131I uptake tests with intra-therapeutic 131I uptake in benign thyroid disorders.

Authors:  Falk Gühne; Christian Kühnel; Martin Freesmeyer
Journal:  Endocrine       Date:  2017-03-07       Impact factor: 3.633

2.  To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.

Authors:  Sandy Srinivas; Andrei Iagaru
Journal:  J Nucl Med       Date:  2021-08-26       Impact factor: 10.057

3.  Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.

Authors:  C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald
Journal:  Endocrine       Date:  2020-03-16       Impact factor: 3.633

Review 4.  SPECT/CT in the Treatment of Differentiated Thyroid Cancer.

Authors:  Sang-Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-02-08

5.  Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.

Authors:  Christian Happel; Wolfgang Tilman Kranert; Hanns Ackermann; Ina Binse; Benjamin Bockisch; Daniel Gröner; Ken Herrmann; Frank Grünwald
Journal:  Endocrine       Date:  2018-12-31       Impact factor: 3.633

6.  Transcriptional response of BALB/c mouse thyroids following in vivo astatine-211 exposure reveals distinct gene expression profiles.

Authors:  Nils Rudqvist; Toshima Z Parris; Emil Schüler; Khalil Helou; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2012-06-14       Impact factor: 3.138

7.  Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.

Authors:  Seunggyun Ha; So Won Oh; Yu Kyeong Kim; Do Hoon Koo; Young Ho Jung; Ka Hee Yi; June-Key Chung
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

8.  Values of (99m)Tc-methoxyisobutylisonitrile imaging after first-time large-dose (131)I therapy in treating differentiated thyroid cancer.

Authors:  Xiaomei Pan; Dong Duan; Yuquan Zhu; Hua Pang; Lili Guan; Zhixiang Lv
Journal:  Onco Targets Ther       Date:  2016-02-10       Impact factor: 4.147

9.  Statistical and radiobiological analysis of the so-called thyroid stunning.

Authors:  Stephan Walrand; Michel Hesse; François Jamar
Journal:  EJNMMI Res       Date:  2015-11-19       Impact factor: 3.138

10.  ⁹⁹mTcO₄--, auger-mediated thyroid stunning: dosimetric requirements and associated molecular events.

Authors:  Béatrice Cambien; Philippe R Franken; Audrey Lamit; Thibault Mauxion; Peggy Richard-Fiardo; Julien Guglielmi; Lydie Crescence; Bernard Mari; Thierry Pourcher; Jacques Darcourt; Manuel Bardiès; Georges Vassaux
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.